RT @MichaelAlbertMD: 🧠 Tirzepatide doesn’t just reduce appetite—it rewires the brain. - - -.A new Nature Medicine Phase 1 RCT (n=114) explo….

Hemodynamic guided and device free interatrial shunting for HFpEF - a simpler approach?.

Not all weight loss is good in HFpEF. Unintentional weight loss is different than therapeutic weight loss in HFpEF.

Clinically we use wedge pressure to estimate LA pressure during RHC. In a large transeptal hemodynamic series we show that wedge pressure can be higher than true LAP likely due to pulmonary venous disease and collaterals with implications for PH diagnosis.

More evidence that we should be moving away from peak VO2 at max exertion to understand clinically relevant exercise intolerance and patient symptoms. When was the last time a patient wanted to improve their “peak VO2” as opposed to worrying about symptoms during ADLs?.

Importance of submaximal exercise performance and lactate threshold during early exercise in HFpEF. Early lactate generation linked to hemodynamic and ventilatory differences with early exercise, and not not apparent at peak exertion.

More evidence that not all group 1 PH is the same. In the blue journal we show how clinical gp 1 PH with high HFpEF probability is metabolomically distinct from traditional gp 1 PH, and more similar to clinical HFpEF. @ATSBlueEditor @MayoClinicCV

RT @matslassen: Pooled analysis of obesity and kidney outcomes from 4 HFpEF RCTs now in @JACCJournals . 👥 n=16,919. ⬆️ waist circumference….

RT @mvaduganathan: 🔥 #CONFIDENCE in @NEJM. Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T….

RT @CircHF: Higher HFpEF probability in group 3/4 PH is associated with dynamic PCWP abnormalities, worse functional status and quality of….

Patient with lung disease or sleep apnea often develop precapillary PH considered group 3/4 PH. Here we show that dynamic PCWP abnormalities are very common in these pts. Trials of HFpEF therapies are needed. @CircHF @MayoClinicCV .

RT @novitskiynic: 🔥HOT #HeartFailure2025 PRAISE-HFrEF. 📍No suggestion of⬆️ HFH or ☠️ with GLP1-RA use at diabetes doses.📍Probable safety of….

RT @mvaduganathan: #VICTORIA demonstrated benefits of sGC stimulator vericiguat in recent worsening HF & led to its #FDA approval in '21. N….

RT @mvaduganathan: “What’s Old is New Again!” - @CMichaelGibson . The MR / aldosterone axis remains in central focus for the *treatment* an….

RT @EricTopol: Just published @NEJM .A randomized trial of Semaglutide (Ozempic) vs Tirzepatide (Mounjaro, Zepbound) at max doses demonstra….

RT @JACCJournals: Spoiler alert: In #HFpEF, it's the fat, not the sugar 🍩 Dr. Yogesh N.V. Reddy's, @yreddyhf, latest data crushes the myth….

RT @drjohnm: A really important editorial in JAMA regarding the next big area of low-value, potentially harmful intervention -- on tricuspi….

RT @RyanTedfordMD: ❤️‍🔥 The 5th Charleston HFpEF Conference is July 18-20. Register & book today! Don't miss insights from @robmentz, @nosh….